mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast

1. Moderna beats Q3 loss estimates, reporting a $0.51 loss instead of $2.02. 2. Quarterly sales of $1.02 billion exceeded expectations, despite a 45% YoY decline. 3. COVID vaccine sales contributed $971 million, down significantly from previous year. 4. Cost of sales dropped by 60%, improving operational efficiency and profitability. 5. Plans to submit approvals for mRNA-1010 and mRNA-1083 by early 2026.